Clex

Quick links to important sections

Clex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clex

Property Description
Active ingredient Cefaclor
Form Oral capsule, tablet, or suspension
Pharmacological class Second-generation cephalosporin antibiotic
Common use Elimination of bacterial infections
Origin Semisynthetic

Clex is a systemic prescription drug utilized for the elimination of bacterial infections, whose active pharmaceutical ingredient is Cefaclor. This compound is classified fundamentally as an antibiotic, specifically belonging to the second-generation cephalosporin group, which is itself part of the broader beta-lactam antibacterial family. The Clex trade name is often associated with the oral capsule and liquid suspension forms of Cefaclor, emphasizing its oral delivery method for systemic treatment.

Definition and Pharmacological Classification

Cefaclor is highly effective against a variety of susceptible Gram-positive and Gram-negative bacteria due to its broad-spectrum capability. Its utility in treating common infections is clinically recognized, confirming its established role in medical practice. This positioning differentiates second-generation cephalosporins by providing therapeutic coverage expanded to target certain pathogens not fully susceptible to older, first-generation agents.

Composition, Origin, and Forms

The foundation of Clex is Cefaclor, a semisynthetic compound that serves as the single-ingredient product responsible for the therapeutic action. It is derived from natural starting materials that undergo specific chemical modification to achieve its final stability and enhanced antibacterial efficacy.

For patient administration, Cefaclor is available for oral use in forms such as the oral capsule and oral tablet, as well as an oral suspension for systemic delivery. The range of forms ensures flexible administration for targeting infection sources, such as those that may occur in the respiratory tract or the skin.

General Purpose of This Antibiotic

The main purpose of Clex is to exert a bactericidal action, which means it actively targets and kills the susceptible bacteria causing the infection throughout the body, rather than merely halting their growth. Beta-lactam antibiotics, including Cefaclor, have a demonstrated capacity to rapidly disrupt the bacterial cell wall, leading to the efficient death of the pathogen. Its destructive mechanism is why Clex is relied upon for the swift elimination of infectious bacteria.

Regulatory References

  1. clinically recognized
  2. bactericidal action
  3. oral suspension

What side effects are possible with Clex?

Possible Side Effects and Safety Information

The official safety profile for Cefaclor (Clex) is based on government regulatory documents, which classify adverse reactions by frequency and affected body system. The most Common adverse reactions, occurring in up to 1 in 100 patients, include gastrointestinal disturbances such as diarrhoea, nausea, vomiting, and abdominal discomfort, as well as headache.


Regulatory Classification of Adverse Reactions

Adverse events are grouped into System-Organ Classes (SOC), including Gastrointestinal, Immune System, Skin and Subcutaneous Tissue, and Nervous System disorders. Events classified as Rare may involve transient changes in blood counts or mild elevations of liver enzymes (AST, ALT) and signs of reversible interstitial nephritis.


Serious Adverse Reactions and Key Safety Constraints

The regulatory label documents Serious Adverse Reactions, which are rare but clinically significant. These include severe allergic reactions like anaphylaxis and life-threatening skin conditions such as Stevens-Johnson syndrome and Toxic epidermal necrolysis. Severe intestinal inflammation, Pseudomembranous Colitis, is also officially documented. Symptoms of this condition can occur during therapy or even weeks after cessation.


Population-Specific Safety Notes

The safety profile includes constraints for specific groups. The label states that serum sickness-like reactions have been reported more frequently in children than in adults. Patients with renal impairment are at a higher risk for neurotoxicity and seizures. Cefaclor is contraindicated in individuals with a known history of severe allergic reaction to penicillin or other cephalosporins due to potential cross-hypersensitivity.

Overdose and Emergency Response

Overdose and when to seek help

Overdose management for Cefaclor (Clex) is guided by the potential for both common and severe manifestations documented in regulatory labeling.

Documented Manifestations and Severe Risks

Clinical Presentation Official Regulatory Statement
Common Presentation Symptoms are often non-specific, primarily involving gastrointestinal disturbances such as nausea, vomiting, diarrhea, and epigastric distress (stomach pain).
Severe Risks The primary severe risk is seizures (convulsions), which is a known neurotoxic risk for the cephalosporin antibiotic class, particularly at high systemic concentrations.
Specific Susceptibility Individuals with impaired renal function are at a heightened risk for these severe neurological effects due to compromised drug clearance.

Emergency Actions and Management

Regulatory authorities require that any suspected overdose warrants immediate medical attention. Contacting a poison control center is advised for guidance.

Urgent escalation is required if the individual exhibits life-threatening signs. You must call emergency services immediately if the affected person has collapsed, had a seizure, is experiencing trouble breathing, or can't be awakened.

Because no specific antidote is known, the management strategy is focused on supportive therapy to maintain vital functions. For recent, large ingestions (more than five times the normal total daily dose), procedural measures such as gastric lavage may be considered. For severe cases, the drug is known to be partially removable by haemodialysis.

Therapeutic Uses of Clex

What Clex Treats: Main Uses and Benefits

The medication is commonly used across conditions presenting with acute episodes caused by susceptible bacteria. It is considered relevant in contexts involving heightened systemic burden and symptoms that create noticeable physiological strain, providing support that helps ease the overall symptom burden.

The medication is generally applied across domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, such as high fever, severe sore throat, painful urination (dysuria), and localized swelling. Clex assists with maintaining functional stability and supports the management of acute symptomatic episodes.

It is commonly used to address bacterial infections across several key areas, including upper and lower respiratory tract infections, acute otitis media (middle ear infection), urinary tract infections (UTIs), and uncomplicated skin and soft tissue infections. By providing supportive relief, Clex helps patients cope more steadily with difficult episodes.


Symptomatic Focus: Acute Localized Pain

Clex is commonly used to help with pronounced physical symptoms, including ear pain (otalgia) linked to middle ear infections, and discomfort associated with lower urinary tract infections. This use is relevant for managing symptoms that interfere with daily comfort.

Regulatory References

  1. NIH DailyMed Label for Cefaclor

Eligibility and Restrictions for Use

Who Can and Cannot Use Clex?

The determination of who can safely and appropriately use a medicine is based on specific criteria established in governmental regulatory documents.

Contraindicated Populations (Must Not Use)

Clex is formally contraindicated and must not be used by individuals with a documented hypersensitivity or severe allergic reaction to the active ingredient or any excipients contained in the formulation. Use in these patients is prohibited due to the risk of life-threatening reactions such as anaphylaxis.

Restricted and Special Populations

Population Category Eligibility Status (Regulatory)
Age (Pediatric) Use is not established or not recommended for children under a specified age (e.g., 6 years old), or for populations where pediatric studies have not been completed.
Renal Impairment Use requires special consideration and possible dose adjustment, particularly in cases of severe kidney dysfunction (e.g., CrCl < 30 mL/min), as the drug may be primarily cleared by the kidneys.
Pregnancy/Lactation Eligibility is often designated as use only if clearly needed (e.g., Category B or similar language), with specific safety data required before use during pregnancy or while breastfeeding.

These restrictions define the boundaries of use for Clex, ensuring it is reserved for the approved population where the drug’s benefits are understood to outweigh potential, documented risks. All use should align strictly with the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific patterns that alter Cefaclor exposure and modify the effects of co-administered products. These interactions are categorized based on their mechanism and resulting clinical requirement.

Pharmacokinetic and Clearance Alterations

Co-administration with Probenecid is documented to inhibit the drug’s renal excretion, a transporter-mediated effect that leads to increased and prolonged Cefaclor serum concentrations. For patients with markedly impaired renal function, the drug’s half-life is officially noted to be prolonged, reflecting an altered clearance rate in this population.

Documented Pharmacodynamic Effects

Interactions with oral anticoagulants, such as Warfarin, have been associated with reports of increased prothrombin time with or without clinical bleeding. Additionally, the efficacy of estrogen-containing oral contraceptives may be decreased due to the potential for Cefaclor to alter intestinal flora.

Administration Timing and Product Interactions

The interaction with certain product formulations requires mandatory timing separation. Aluminum or magnesium hydroxide-containing Antacids must not be taken within one hour of Cefaclor extended-release tablets due to evidence of diminished drug absorption. Conversely, the extended-release tablet formulation must be administered with food to achieve optimal total drug exposure. Cefaclor is also documented to cause a false-positive reaction for glucose in the urine when tested using copper reduction methods.

Mechanism of Action

️ Irreversible Inhibition of Bacterial Cell Wall Synthesis

Cefaclor exerts its effect by acting as a covalent inhibitor of Penicillin-Binding Proteins (PBPs), bacterial enzymes crucial for constructing the cell wall. This targeted action blocks the final stage of peptidoglycan cross-linking, resulting in a defective cell wall structure.

Initiation of Lytic Bactericidal Cascade

The result of blocking cell wall construction is defective structural assembly, which is associated with the activation of bacterial autolytic enzymes. This mechanistic cascade leads to the rupture and destruction of the bacterial cell through osmotic pressure, achieving the core bactericidal activity.

Constraints by Bacterial Defense Systems

The mechanism is constrained by bacterial resistance, primarily the production of beta-lactamase enzymes. These enzymes chemically inactivate Cefaclor before it can bind to the PBPs, which compromises the cell wall-targeting mechanism in resistant strains.

Dosage and Administration Information

How to Use Clex

Clex, whose active ingredient is Cefaclor, is a prescription antibiotic that is utilized exclusively via oral administration. The medication is available in several high-level forms, including immediate-release (IR) capsules and oral suspension, as well as an extended-release (ER) tablet formulation.


Official Dosing and Frequency Patterns

The standard adult dosing regimens for the immediate-release form generally start at 250 mg per dose, with the dosage potentially increased to 500 mg per dose for more severe infections. The frequency pattern for administration is typically established as three times daily (every 8 hours, t.i.d.). However, alternative twice-daily (b.i.d., every 12 hours) regimens are also approved for specific clinical scenarios.

For the extended-release tablets, the dosing is consistently scheduled for twice daily administration, with total daily amounts ranging from 750 mg to 1000 mg. The treatment course for all forms of Cefaclor is a fixed duration, generally lasting between 7 to 10 days.


Administration Conditions and Handling

The relationship to meals varies by formulation. The immediate-release capsules or suspension may be taken with or without food. Conversely, the extended-release tablets must be administered with meals to ensure proper drug absorption. A critical procedural constraint is that ER tablets must be swallowed whole and cannot be cut, crushed, or chewed, as this compromises the product's extended-release properties.

Dosage adjustment is not usually necessary for older adults or individuals with routine renal impairment, provided kidney function is otherwise stable.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clex (Cefaclor)

Evidence for Use in Respiratory Tract and Ear Infections

Research explored Cefaclor for these types of infections, including numerous short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were used in research exploring how symptoms change over time for conditions such as acute otitis media (middle ear infection) and upper and lower respiratory tract infections. The discussion will focus on the primary endpoints that researchers measured, such as the rate of clinical change in symptoms.

In these studies, researchers monitored changes in symptoms, such as the reduction of fever or ear pain, and also monitored the bacteriological eradication rate to assess the clearance of targeted bacteria. These findings describe patterns observed in the studies related to how symptoms evolved in the observed populations. For lower respiratory tract infections, such as pneumonia, research examined outcomes related to systemic or functional imbalance, specifically looking at clinical success rates over a 7- to 14-day observation period.

The research provides limited insight into long-term outcomes after the period of observation. The follow-up durations were limited, meaning that information about infection recurrence or the durability of the effect years later is not well established. Evidence quality varies across studies.


Evidence for Use in Urinary and Skin Infections

Here, we will detail the evidence base related to Clex as studied for urinary tract infections (UTIs) and uncomplicated skin and soft tissue infections. Cefaclor was evaluated in studies that included prospective clinical trials, often comparative in nature. Research examined outcomes related to physical discomfort and the rate of bacteriological eradication (measured absence of bacteria in the urine or skin tissue) at defined post-treatment evaluations.

Data for these indications appears to be moderate, as much of the evidence relies on older clinical trial data and pooled efficacy summaries. The research primarily describes findings related to acute, uncomplicated cases. Comparative evidence is lacking for some modern therapeutic standards, and data for certain groups, such as those with complex or recurrent infections, remain insufficient.

Key Studies & References

  1. Cefaclor FDA Label and Indications for Use (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Clex (FAQ)


Q: How quickly should I expect Clex to start working?

A: Studies on Clex in healthy individuals show that the drug quickly reaches its highest concentration in the bloodstream, usually within 30 to 60 minutes after taking the immediate-release form. While the active drug is present in the bloodstream shortly after taking it, the clinical effect, such as the improvement of symptoms, is influenced by the specific infection and individual patient factors.


Q: Is it normal to feel tired when starting Clex?

A: Tiredness is not listed as a common side effect in the official product information. However, regulatory documents note rare reports of central nervous system effects, such as somnolence (drowsiness), dizziness, or confusion. If any concerning side effects or symptoms, including unusual tiredness, are experienced, the prescribing healthcare provider should be consulted.


Q: Does Clex need to be refrigerated?

A: The storage requirements depend on the form of the medication. The capsules, tablets, and dry powder for suspension should be kept at a controlled room temperature, typically not above 30 C. The liquid suspension, once it has been mixed, must be stored in a refrigerator (at 2 C to 8 C) and should never be frozen.


Q: Does Clex interact with common supplements like Vitamin D or magnesium?

A: Official information indicates that antacids containing magnesium or aluminum hydroxide should not be taken within one hour of the Clex extended-release tablets, as they can reduce the amount of medicine absorbed. Interactions with other specific supplements, such as Vitamin D, are not detailed in the official product labeling.


Q: Can Clex be used during pregnancy, and what are the risks?

A: Cefaclor is generally classified as a Category B drug in the US. This indicates that the drug should be used only if clearly needed. Decisions regarding the use of this medication during pregnancy or while breastfeeding should be based on a thorough discussion with a healthcare provider to review the individual risk-benefit assessment.


Q: What is the shelf life of Clex?

A: The solid forms (capsules and tablets) are stable until the expiration date printed on the packaging, provided they are stored correctly. For the liquid suspension, the product must be discarded 14 days after it is first mixed, even if there is medication remaining.


Q: How does Clex affect liver function?

A: Regulatory documents indicate that Clex is associated with rare, transient occurrences of slight elevations in liver enzyme values, such as AST and ALT. Rare cases of transient hepatitis and cholestatic jaundice have also been reported. These changes are often transient and have been observed to resolve after cessation of the medication.


Q: Are there any long-term side effects associated with Clex use?

A: Clex is typically prescribed for short courses. Official documentation warns that prolonged use may result in the growth of other, non-susceptible organisms. It is important to note that severe intestinal inflammation (Pseudomembranous Colitis) is a rare but serious adverse reaction documented in the label, which can sometimes appear even weeks after treatment completion.


Q: Why do some people experience bruising while on Clex?

A: In patients who are also taking oral anticoagulants, such as Warfarin, rare reports exist of Clex causing an increase in prothrombin time. Prothrombin time is a measure of how quickly blood clots. Patients taking both medications are advised to monitor for any unusual bruising or bleeding.


Q: Are there specific foods I should avoid when taking Clex?

A: The extended-release tablets must be taken with a meal to ensure the medicine is properly absorbed. Aside from the required timing with food for the ER form, official product information does not place specific restrictions on foods. However, antacids containing aluminum or magnesium should not be taken at the same time.


Q: Does Clex cause stomach upset or nausea?

A: Yes, gastrointestinal symptoms are the most common adverse reactions reported in studies, occurring in about 2.5% of patients. These can include diarrhea, nausea, vomiting, and abdominal discomfort. These effects are generally mild and temporary.


Q: Does Clex interact with birth control pills?

A: Official information states that the effectiveness of estrogen-containing oral contraceptives may be reduced while taking Clex. This is thought to be due to the antibiotic potentially changing the natural bacteria in the intestines. Patients should consult their healthcare provider to determine if they need to use an additional method of contraception while on this treatment.


Q: What if I vomit shortly after taking my Clex pill?

A: Official regulatory information does not provide specific instructions for how to handle vomiting that occurs shortly after taking a dose. Procedural guidance for dosing errors, such as vomiting after a dose, must be obtained from the prescribing healthcare professional or pharmacist.


Q: How long does Clex stay in your system after the last dose?

A: In individuals with normal kidney function, Clex has a short half-life, meaning it is quickly eliminated from the body. The majority of the drug is excreted in the urine, generally within 8 hours of administration.


Q: Are there studies on Clex use in children?

A: Yes, Clex is approved for use in pediatric patients with specific dosing guidelines for the suspension form. However, regulatory information notes that the capsule form has not been studied in infants younger than 1 month, and its safety has not been established for this age group.


Q: Can Clex affect dental procedures?

A: Patients are generally advised to inform all healthcare providers, including dentists, that they are taking Clex. This is particularly relevant because Clex can potentially increase the effect of oral anticoagulants, which may be a concern for certain dental procedures where bleeding is possible.


Q: Is it possible to overdose on Clex?

A: Yes, an overdose is possible with Clex. The symptoms that usually follow an overdose include nausea, vomiting, diarrhea, and epigastric distress (discomfort in the upper abdomen). In cases of accidental overdose, medical attention is required. Management may involve clinical interventions to reduce the absorption of the drug.


Q: Why is Clex considered a low molecular weight drug?

A: Cefaclor has a molecular weight of approximately 367.8 g/mol. In pharmacological terms, Cefaclor is considered a small molecule drug based on this size. This small size helps explain the drug's classification as a 'small molecule drug' in pharmacology.


Q: How is Clex administered if it's an injection?

A: Clex (Cefaclor) is only available and administered for oral use. It is prescribed as a capsule, tablet, or liquid suspension and is not available as an injection.


Q: What are the common injection sites for Clex?

A: Clex is not an injectable medication. It is administered orally as a capsule, tablet, or liquid suspension, and therefore it does not have any designated injection sites.

How should Clex be stored and disposed of?

Storage Conditions

Storage requirements for Cefaclor (Clex) vary by formulation. The dry powder for suspension, capsules, and tablets must be stored at Controlled Room Temperature, typically not exceeding 30 C (86 F), and must be protected from both moisture and light.

Once reconstituted, the liquid suspension must be refrigerated at 2 C to 8 C (36 F to 46 F) and must not be frozen.

Formulation Required Storage Condition Stability Limit
Dry Powder/Solid Forms Not above 30 C, protected from light/moisture Until Expiration Date
Reconstituted Liquid Refrigerated (2 C–8 C), Do Not Freeze Discard after 14 days

Handling and Disposal

All forms must be kept in the original, tightly closed container and out of the reach of children. Unused or expired medication, including the liquid suspension remaining after 14 days, must not be disposed of via household waste or wastewater. Consult a pharmacist for proper disposal in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clex found in:

A-Z Index: